OR WAIT null SECS
April 25, 2025
Article
A major factor of type 2 diabetes mellitus, dyslipidemia can potentially be prevented by closely monitoring lipid profiles.
Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.
April 24, 2025
Researchers indicated an association between the index and 365-day mortality.
April 22, 2025
Video
Christie M. Ballantyne, MD, discusses the role of plozasiran in managing elevated triglycerides and reducing pancreatitis risk.
April 14, 2025
Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.
A single infusion of VERVE-102 gene editing therapy achieved dose-dependent lowering in blood PCSK9 and LDL-C in initial results from the Heart-2 trial.
April 11, 2025
Payal Kohli, MD, explores how evolving tools and strategies in lipid management are reshaping preventive cardiology.
Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.
VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.
April 10, 2025
Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.
